Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
At present, the treatment of non-squamous cell lung cancer is based on chemotherapy with
platinum eventually associated with bevacizumab. A new treatment begins at progression.
In colo-rectal metastatic cancer, it was demonstrated that the first-line of treatment could
be administered according to a stop and go strategy respecting therapeutic breaks between
sequences of identical treatment. During these therapeutic breaks, a treatment of maintenance
is possibly better than an absence of treatment. These plans benefit to the patients in terms
of efficiency but also in terms of toxicity, in particular neurological.
The question is to know if this strategy is feasible in lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique